AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMMUTEP LTD

0.032

-0.001-3.03%

Volume:24.95M

Turnover:785.01K

Market Cap:47.16M

PE:-0.59

High:0.034

Open:0.034

Low:0.030

Close:0.033

52wk High:0.470

52wk Low:0.028

Shares:1.47B

Float Shares:1.23B

Volume Ratio:2.52

T/O Rate:2.03%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.054

EPS(LYR):-0.054

ROE:-77.31%

ROA:-42.45%

PB:0.77

PE(LYR):-0.59

Loading ...

Overview Company News Filings

Immutep Ltd - Has 180 Days Until October 26, 2026 to Regain Nasdaq Compliance

THOMSON REUTERS

Immutep Ltd - Remains Listed on ASX; Nasdaq Notice Does Not Affect ASX Trading

THOMSON REUTERS

Immutep Says Bank of New York Mellon Increases Stake

MT Newswires Live

Immutep says ASCO accepts poster on eftilagimod alfa in metastatic cancer patients

Immutep Says JPMorgan Chase Cut Stake; Shares Down 9%

MT Newswires Live

ASX Runners of the Week: Bison, Genetic Signatures, Narryer & Immutep

The West Australian

Immutep files beneficial ownership Form 3 for director Elisabeth Amanda Boyce

BUZZ-Australia's Immutep extends gain on FDA orphan drug status for cancer drug

BRIEF-Immutep Ltd Says FDA Granted Orphan Drug Designation For Eftilagimod alfa In Soft Tissue Sarcoma

Immutep wins FDA orphan drug designation for eftilagimod alfa in soft tissue sarcoma

Immutep Ltd - FDA Grants Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma

THOMSON REUTERS

Immutep CEO Marc Voigt files initial beneficial ownership statement

Immutep files Form 3 for COO Deanne Diem Miller initial beneficial ownership statement

Immutep Says JPMorgan Reduces Stake

MT Newswires Live

Immutep director Peter Andrew Meyers files initial beneficial ownership statement

BRIEF-Immutep Discontinues Phase III Tacti-004 Study In Non-Small Cell Lung Cancer

Immutep Ltd - Discontinues Phase Iii Tacti-004 Study in Non-Small Cell Lung Cancer

THOMSON REUTERS

Immutep Ltd - Estimates Review Process Could Extend Into Q3 2026

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/IMM.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.032,"timestamp":1790921520000,"preClose":0.033,"halted":0,"volume":24951559,"delay":0,"changeRate":-0.030303030303030328,"nameEN":"IMMUTEP LTD","floatShares":1228247159,"shares":1473721306,"eps":-0.0539,"marketStatus":"Closed","change":-0.001,"latestTime":"10-02 16:12:00 AEST","open":0.034,"high":0.034,"low":0.03,"amount":785008,"amplitude":0.121212,"askPrice":0.032,"askSize":1097305,"bidPrice":0.03,"bidSize":2117133,"shortable":3,"etf":0,"ttmEps":-0.0539,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791154800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.033,"openAndCloseTimeList":[[1790899200000,1790920800000]],"volumeRatio":2.523883,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMM.AU","preClose":0.033,"auctionPrice":0.031,"auctionVolume":1821066,"auctionTime":1790921400253,"referencePrice":0.032,"referenceTime":1790923320429,"auction":3,"marketStatus":"盘后竞价","timestamp":1790921400253}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1228247159,"roa":"-42.45%","roe":"-77.31%","lyrEps":-0.0539,"volumeRatio":2.523883,"shares":1473721306,"dividePrice":0,"high":0.034,"amplitude":0.121212,"preClose":0.033,"low":0.03,"week52Low":0.028,"pbRate":"0.77","psRate":"2.37","week52High":0.47,"institutionHeld":0,"latestPrice":0.032,"committee":0.317265,"eps":-0.0539,"divideRate":0,"volume":24951559,"delay":0,"ttmEps":-0.0539,"open":0.034,"prevYearClose":0.415,"prevWeekClose":0.036,"prevMonthClose":0.034,"prevQuarterClose":0.034,"fiveDayClose":0.036,"twentyDayClose":0.048,"sixtyDayClose":0.051,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2631531573","title":"Immutep Ltd - Has 180 Days Until October 26, 2026 to Regain Nasdaq Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2631531573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631531573?lang=en_us&edition=fundamental","pubTime":"2026-04-30 07:22","pubTimestamp":1777504933,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nFWN41C1U5:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631457353","title":"Immutep Ltd - Remains Listed on ASX; Nasdaq Notice Does Not Affect ASX Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2631457353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631457353?lang=en_us&edition=fundamental","pubTime":"2026-04-30 07:22","pubTimestamp":1777504933,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nFWN41C1U5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630337859","title":"Immutep Says Bank of New York Mellon Increases Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2630337859","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630337859?lang=en_us&edition=fundamental","pubTime":"2026-04-27 08:21","pubTimestamp":1777249274,"startTime":"0","endTime":"0","summary":"Immutep  received notice that Bank of New York Mellon and its affiliated entities increased their holdings in the company to 21.11% from 20.08%, according to a Monday filing with the Australian bourse.Bank of New York Mellon and its affiliates now owns over 311 million shares in the company, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK","LU0130102774.USD","BK4135","LU1699723380.USD","IMM.AU","LU0130517989.USD","BK4585","LU0648001328.SGD","BK4559","BK7067","LU0980610538.SGD","LU1201861249.SGD","LU1571399168.USD","LU0477156953.USD","BK7508","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629985870","title":"Immutep says ASCO accepts poster on eftilagimod alfa in metastatic cancer patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2629985870","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629985870?lang=en_us&edition=fundamental","pubTime":"2026-04-22 10:20","pubTimestamp":1776824450,"startTime":"0","endTime":"0","summary":"Immutep flagged an abstract on its cancer immunotherapy candidate eftilagimod alfa for poster presentation at ASCO 2026, with results scheduled for May 30.Poster data are set to show cumulative clinical and translational findings that the drug drives rapid, sustained immune-cell activation in metastatic cancer patients.Immutep expects the analysis to link immune activation signals with better overall survival outcomes across multiple late-stage cancer studies, supporting the program’s clinical rationale.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on April 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDLb644WR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628205632","title":"Immutep Says JPMorgan Chase Cut Stake; Shares Down 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628205632","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628205632?lang=en_us&edition=fundamental","pubTime":"2026-04-17 14:04","pubTimestamp":1776405844,"startTime":"0","endTime":"0","summary":"Immutep (ASX:IMM) said JPMorgan Chase and its affiliates cut their stake in the company on Tuesday to 5.43% or about 80.1 million shares from 6.94% or roughly 102.3 million shares, according to a Friday filing with the Australian bourse.Shares of Immutep were down 9% in recent Friday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2237443978.SGD","LU2106854487.HKD","IE00BZ1G4Q59.USD","LU0345770308.USD","LU0787776722.HKD","IE00B1BXHZ80.USD","LU1551013425.SGD","LU2746668974.SGD","LU2023250843.SGD","IMM.AU","LU0211327993.USD","LU0211331839.USD","LU0868494617.USD","LU0265550359.USD","JPO","SG9999002232.USD","LU0267386448.USD","LU0820561818.USD","LU2236285917.USD","LU0882574139.USD","LU1145028129.USD","IE00BYXW3230.USD","LU2211815571.USD","LU1267930490.SGD","SG9999002224.SGD","LU1974910355.USD","LU2242649171.HKD","LU0203347892.USD","LU0859254822.USD","IE00B1XK9C88.USD","LU0971096721.USD","LU0048584097.USD","BK4504","BK4588","BK7067","JPMO","IE00BLSP4452.SGD","LU2430703251.USD","BK4581","BK4516","LU2430703178.SGD","LU2462157665.USD","JPM","LU1548497426.USD","LU2417539215.USD","LU2264538146.SGD","LU1366192091.USD","LU0251132253.USD","LU0820562030.AUD","LU1261432733.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628278514","title":"ASX Runners of the Week: Bison, Genetic Signatures, Narryer & Immutep","url":"https://stock-news.laohu8.com/highlight/detail?id=2628278514","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628278514?lang=en_us&edition=fundamental","pubTime":"2026-04-17 06:27","pubTimestamp":1776378463,"startTime":"0","endTime":"0","summary":"The Bulls N’ Bears ASX Runner of the Week is… Bison Resources, which exploded on debut, as punters piled into its prime Nevada gold-silver projects amid ongoing fuel security chaos.","market":"us","thumbnail":"https://images.thewest.com.au/publication/C-22156398/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22156398/f3ba145e5bde0aa97d4b38a2ae55d7e52f82c4d9.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/asx-runners-of-the-week-bison-genetic-signatures-narryer-immutep-c-22156398","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/asx-runners-of-the-week-bison-genetic-signatures-narryer-immutep-c-22156398","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["DZZ","BTGD","CEF","DUST","PHYS","DULL","BK7508","GSS.AU","IAUM","NYM.AU","OUNZ","DBC","GLTR","BK7048","GBUG","GDXU","GLL","BK4535","GDXY","UGL","AAAU","JDST","GDXD","BK4588","BSR.AU","IAU","BK7067","GOLY","DGP","BK7501","GDX","GDXJ","GLDM","IMM.AU","XME","SGOL","PICK","BK4183","USG","BK7095","ODD","BK4585","BK7104","IE0009354923.USD","RING","FGDL","BEGS","IAUI","JNUG","BAR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627299905","title":"Immutep files beneficial ownership Form 3 for director Elisabeth Amanda Boyce","url":"https://stock-news.laohu8.com/highlight/detail?id=2627299905","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627299905?lang=en_us&edition=fundamental","pubTime":"2026-04-16 18:06","pubTimestamp":1776334014,"startTime":"0","endTime":"0","summary":"Immutep director Elisabeth Amanda Boyce filed an initial U.S. SEC Form 3 reporting 423,288 ordinary shares held directly as of March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL5J4M9T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627257758","title":"BUZZ-Australia's Immutep extends gain on FDA orphan drug status for cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2627257758","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627257758?lang=en_us&edition=fundamental","pubTime":"2026-04-16 10:24","pubTimestamp":1776306262,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Immutep extends gain on FDA orphan drug status for cancer drug** Shares of Australian biotechnology firm Immutep IMM.AX rise as much as 22.2% to A$0.075, their highest since March 6**","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nL4N40Z06C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627476113","title":"BRIEF-Immutep Ltd Says FDA Granted Orphan Drug Designation For Eftilagimod alfa In Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2627476113","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627476113?lang=en_us&edition=fundamental","pubTime":"2026-04-15 09:21","pubTimestamp":1776216119,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep Ltd Says FDA Granted Orphan Drug Designation For Eftilagimod alfa In Soft Tissue SarcomaApril 15 (Reuters) - Immutep Ltd IMM.AX:IMMUTEP LTD - FDA GRANTS ORPHAN DRUG DESIGNATION FOR EFTILAGIMOD ALFA IN SOFT TISSUE SARCOMASource text: ID:nASX4fL5nrFurther company coverage: IMM.AX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nFWN40X171:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627753974","title":"Immutep wins FDA orphan drug designation for eftilagimod alfa in soft tissue sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2627753974","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627753974?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:41","pubTimestamp":1776213697,"startTime":"0","endTime":"0","summary":"Designation supports potential late-stage development in resectable disease following Phase II EFTISARC-NEO results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on April 15, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL9NDDby:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627207654","title":"Immutep Ltd - FDA Grants Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2627207654","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627207654?lang=en_us&edition=fundamental","pubTime":"2026-04-15 07:27","pubTimestamp":1776209236,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40X171:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627984244","title":"Immutep CEO Marc Voigt files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2627984244","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627984244?lang=en_us&edition=fundamental","pubTime":"2026-04-14 09:58","pubTimestamp":1776131907,"startTime":"0","endTime":"0","summary":"Immutep CEO, CFO, executive director Marc Voigt filed an initial Form 3 showing 14,792,145 ordinary shares held.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL9blLH5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627343124","title":"Immutep files Form 3 for COO Deanne Diem Miller initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2627343124","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627343124?lang=en_us&edition=fundamental","pubTime":"2026-04-13 18:22","pubTimestamp":1776075725,"startTime":"0","endTime":"0","summary":"Immutep COO Deanne Diem Miller filed an initial beneficial ownership statement reporting 2,867,305 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDLbgXFYR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627487792","title":"Immutep Says JPMorgan Reduces Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2627487792","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627487792?lang=en_us&edition=fundamental","pubTime":"2026-04-13 15:25","pubTimestamp":1776065154,"startTime":"0","endTime":"0","summary":"Immutep (ASX:IMM) said JPMorgan and its affiliates have reduced their stake in the company on April 8 to 6.94% or 102.3 million shares from 8.28% or 122.0 million shares, according to a Monday Australian bourse filing.The company's shares were down 10% on market close.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2237443978.SGD","LU0267386448.USD","LU0006306889.USD","LU1145028129.USD","LU2746668974.SGD","LU2417539215.USD","LU0265550359.USD","BK4534","JPO","SG9999002224.SGD","IE00BHPRN162.USD","LU1162221912.USD","IE00BLSP4452.SGD","LU0070302665.USD","IE000M9KFDE8.USD","JPMO","LU0976567544.SGD","LU0048584097.USD","LU2242649171.HKD","LU0942090050.USD","LU1720051108.HKD","LU1894683348.USD","SG9999002232.USD","LU0203345920.USD","IMM.AU","LU0882574139.USD","LU0820561909.HKD","LU0211326755.USD","LU2746668461.USD","LU0345769128.USD","LU0106261372.USD","LU1629891620.HKD","LU2213496289.HKD","LU1974910355.USD","LU2552382215.SGD","LU1084165304.USD","LU2430703178.SGD","LU0640476718.USD","LU0820562030.AUD","IE00BJTD4N35.SGD","LU0310799852.SGD","LU1116320901.HKD","LU2756315318.SGD","IE00BKVL7J92.USD","IE00BYXW3230.USD","LU2054465674.USD","JPM","LU2023250504.SGD","LU0320765489.SGD","LU2023250330.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625399389","title":"Immutep director Peter Andrew Meyers files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2625399389","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625399389?lang=en_us&edition=fundamental","pubTime":"2026-04-08 09:29","pubTimestamp":1775611793,"startTime":"0","endTime":"0","summary":"Immutep director Peter Andrew Meyers filed an initial beneficial ownership statement showing 4,052,173 ordinary shares held directly as of March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL5CrYXc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625998707","title":"BRIEF-Immutep Discontinues Phase III Tacti-004 Study In Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2625998707","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625998707?lang=en_us&edition=fundamental","pubTime":"2026-04-08 09:24","pubTimestamp":1775611490,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep Discontinues Phase III Tacti-004 Study In Non-Small Cell Lung CancerApril 8 (Reuters) - Immutep Ltd IMM.AX:DISCONTINUES PHASE III TACTI-004 STUDY IN NON-SMALL CELL LUNG CANCERESTIMATES R","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40Q17Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625996751","title":"Immutep Ltd - Discontinues Phase Iii Tacti-004 Study in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2625996751","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625996751?lang=en_us&edition=fundamental","pubTime":"2026-04-08 08:06","pubTimestamp":1775606815,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40Q17Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625675489","title":"Immutep Ltd - Estimates Review Process Could Extend Into Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625675489","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625675489?lang=en_us&edition=fundamental","pubTime":"2026-04-08 08:06","pubTimestamp":1775606815,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40Q17Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":58,"code":"91000000","status":"200"}]}}